Analysis

Kezar Life Sciences, Inc. (KZR) Stock Analysis

Kezar Life Sciences, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to KZR.

websiteKZR/analysis/KZR

Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to KZR.

Stock profile

Ticker

KZR

Asset type

Stock

Market cap

$53.9M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Kezar Life Sciences, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • KZR primary listing
  • A40NJT
  • 2KZ0

Latest Kezar Life Sciences, Inc. news

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

PARIS & SOUTH SAN FRANCISCO, Calif., March 12, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at t...

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif., January 09, 2026--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to tre...

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., November 12, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to t...

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver...

SOUTH SAN FRANCISCO, Calif., November 07, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to t...

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

SOUTH SAN FRANCISCO, Calif., October 16, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule thera...

Research sections

Valuation

Review valuation context for Kezar Life Sciences, Inc..

Future growth

Review future growth context for Kezar Life Sciences, Inc..

Past performance

Review past performance context for Kezar Life Sciences, Inc..

Financial health

Review financial health context for Kezar Life Sciences, Inc..

Dividend

Review dividend context for Kezar Life Sciences, Inc..

Management

Review management context for Kezar Life Sciences, Inc..

Ownership

Review ownership context for Kezar Life Sciences, Inc..

Other information

Review other information context for Kezar Life Sciences, Inc..

Community

Review community context for Kezar Life Sciences, Inc..